Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LungMate 002: neoadjuvant toripalimab plus platinum-based chemotherapy in stage II-III NSCLC
ChiCTR1900024014Phase 4Recruiting
- Sponsor
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital of Tongji University
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Department of Thoracic Surgery, Shanghai Pulmonary Hospital of Tongji University. Primary endpoints: Safety and Major pathologic response. Started Aug 2019; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900024014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024014.